Figure 3
Composite figure of secondary outcomes. All data presented as mean±SEM. ES=Cohen’s d effect size. (a) SCoRS Interviewer total score evaluating changes in patient functioning from baseline. Statistically significant changes noted in the encenicline 0.9 mg dose (P=0.011, ES=0.36). Mean baseline values were 37.2, 38.5, and 37.3 in the encenicline 0.27 and 0.9 mg groups and in the placebo group. (b) PANSS Negative Subscale demonstrating dose-dependent change from baseline reaching significance at the encenicline 0.9 mg dose (P=0.028, ES=0.33). Mean baseline values were 17.9, 18.7, and 19.0 in the encenicline 0.27 and 0.9 mg groups and the placebo group.
